OTLK (Outlook Therapeutics) Short Interest


OTLK Outlook Therapeutics Inc OTLK
11 GF Score
Price $1.62
! 6 Warning Signs
View Full Analysis

What is Outlook Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

OTLK vs INO, CBUS, RANI: Short Interest Comparison

For the Biotechnology subindustry, Outlook Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Outlook Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Short Interest falls into.


OTLK
11GF Score
Outlook Therapeutics Inc OTLK
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Outlook Therapeutics Business Description

Other Exchanges 41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
11GF Score

Get the complete analysis for OTLK

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.62
Price